Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Juno Therapeutics
company
About
Juno Therapeutics is a clinical-stage company, develops immunotherapies for the treatment of cancer.
- 251 - 500
Details
- Last Funding Type
- Series A
- Last Funding Money Raised
- $120M
- Industries
- Biotechnology,Clinical Trials,Health Care,Medical,Therapeutics
- Founded date
- Jan 1, 2013
- Number Of Employee
- 251 - 500
- Operating Status
- Active
Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
2
$254M
Juno Therapeutics has raised a total of
$254M
in funding over 2 rounds. Their latest funding was raised on
Aug 5, 2014 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 5, 2014 | Series B | $134M | 1 | — | — | Detail |
| Dec 3, 2013 | Series A | $120M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Juno Therapeutics is funded by 1 investors.
ARCH Venture Partners
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
ARCH Venture Partners
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
